×

Wuhan Jinyintan Hospital � Lopinavir/ritonavir

Lopinavir/ritonavir are HIV protease inhibitors that act synergistically to decrease the amount of HIV in the blood. The combination is used to treat patients with HIV, however, based on animal data, it is also believed to be effective against coronaviruses [1].

An open-label clinical study by Wuhan Jinyintan Hospital in China found no benefit in adding lopinavir-ritonavir therapy to standard care [2].

References

  1. Chan, J. F. W., Yao, Y., Yeung, M. L., Deng, W., Bao, L., Jia, L., … & Cai, J. P. (2015). Treatment with lopinavir/ritonavir or interferon-ß1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. The Journal of infectious diseases, 212(12), 1904-1913.
  2. Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., … & Li, X. (2020). A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine.